2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 387

Rituximab Should be Considered in Rheumatoid Factor Negative Poly-Articular Juvenile Idiopathic Arthritis
Abstract Number: 388

Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Abstract Number: 389

Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry
Abstract Number: 390

Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India
Abstract Number: 391

A Single Centre Experience from India on the Safety and Efficacy of Cipla Etanercept and Intas Etanercept and Its Comparison with Reference Etanercept(Enbrel) in Children with JIA
Abstract Number: 392

Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Abstract Number: 393

Association of Sex, Race and Ethnicity on Disease Outcomes in Juvenile Idiopathic Arthritis Patients
Abstract Number: 394

Effect of BMI on Symptoms and Outcomes in Juvenile Idiopathic Arthritis Patients
Abstract Number: 395

The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Abstract Number: 396

Performance of Disease Activity Measures in Juvenile Spondyloarthritis in a Placebo Controlled Trial with Infliximab
Abstract Number: 397

Comorbidities Associated with Pediatric Psoriatic Arthritis
Abstract Number: 398

Predictors of Clinical Remission with Etanercept in Pediatric Patients with Extended Oligoarticular, Enthesitis-Related Arthritis and Psoriatic Arthritis: Findings from the Clipper Study
Abstract Number: 399

Enthesitis in Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 400

Foot Involvement in Enthesitis-Related Arthritis Subtype of Juvenile Idiopathic Arthritis: Clinical, Radiological and Functional Assessment
Abstract Number: 401

Humoral Immune Response after a Booster Dose with Tdap in Children and Adolescents with Juvenile Idiopathic Arthritis on Anti-TNF and in Healthy Controls

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].